Follow us on
The Hon’ble Supreme Court, through its judgment dated 30th January 2026 in Yash Charitable Trust & Ors. vs Union of India & Ors., has significantly tightened the regulatory framework governing stem cell therapy in India. In response, ICMR has issued a directive mandating strict compliance across all medical institutions, emphasizing that stem cell therapy must now be practiced within clearly defined legal and ethical boundaries.
As per the advisory, stem cell therapy in routine clinical practice is permitted only for disease conditions explicitly approved by the Ministry of Health and Family Welfare (MoHFW) as part of standard care. Any use beyond these approved indications is prohibited in routine practice and can only be undertaken within a research setting. The regulatory pathway depends on the degree of cell manipulation—cases involving more than minimal manipulation fall under CDSCO, while those with lesser manipulation are governed by DHR, along with mandatory approvals from DHR-registered Institutional Ethics Committees and the National Stem Cell Research Regulation Committee.
Furthermore, all stem cell research must be conducted strictly as part of approved clinical trials and adhere to ICMR ethical guidelines. This includes obtaining informed consent, ensuring no financial burden on patients, and providing compensation in case of adverse events. The advisory clearly reiterates that any biomedical research must be approved by an IEC registered with DHR, reinforcing accountability and ethical oversight.
Importantly, any stem cell therapy not included under standard care indications or lacking approval from CDSCO or DHR will be deemed illegal and subject to regulatory and legal action. Authorities have been directed to disseminate this advisory widely among practitioners and institutions to ensure nationwide compliance, marking a decisive step toward curbing unregulated and non-evidence-based use of stem cell therapies in India.
The Medical Bulletin
Leave a Reply